I do feel guilty this morning. I should of urged the children on with a Lizard King proclamation, however, Not Only Have I Predicted Today's Big Rally but tomorrow's possible sell-off as well. So I don't want to be labeled a flip flopper. I am QQQ'd up the ying yang! I'd like to take a moment and ask you all if market -direction wise you have ever ever seen anyone better. Honestly I am more accurate than anyone you see on TV-- I have done it enough times here I think you all know by now you have something very special in the stonedinvestor. His picks may be too sexy for you or do too well incurring massive tax bills as they do.. but his Market timing<-- his market direction <--- His Bull/Bear calls lets just face it-- non paralleled.
Boston Scientific stock climbs as Q2 sales soar on Cardiology, Urology; trims FY22 outlook Jul. 27, 2022 7:37 AM ETBoston Scientific Corporation (BSX) I should never have removed this. I am sorry. One of my biggest faults is impatience. Boston Scientific (NYSE:BSX) stock rose+5%premarket July 27 after the company's Q2resultsbeat analysts estimates despite narrowing FY22 outlook. Q2 adjustedEPSrose +10% Y/Y to $0.44, while net sales grew +5.4% Y/Y to $3.24B. "We hadanother quarter of excellent performance,
Paul Sekhri to join vTv Therapeutics as CEO Jul. 27, 2022 7:28 AM ETvTv Therapeutics Inc. (VTVT) Paul Sekhri has beenappointedas president and CEO of clinical-stage biopharmaceutical company vTv Therapeutics (NASDAQ:VTVT). Sekhri assumes the role on August 1, 2022, replacing interim CEO Rich Nelson, who will continue as EVP, Corporate Development and as a member of the board ofdirectors. He hold nearly 30 years of healthcare experience, including serving as president and CEO of several healthcare companies such as eGenesis, Lycera, Cerimon Pharmaceuticals, as well as senior business development and strategy roles at Sanofi, Teva Pharmaceutical Industries, TPG Biotech, Cerimon, Ariad Pharmaceuticals and Novartis Pharma. The appointment comes at a time when vTv Therapeutics (VTVT) is set to launch Phase 3 pivotal studies for its most advanced product, TTP399. TTP399 has received Breakthrough Therapy designation by the U.S. FDA as an oral adjunctive therapy for the treatment of T1D. I don't know the company nor the man buthe seems to have a real good resume. T1D? You got me some research to be done here but i bet the stk goes up.
This is a name from the old days-- i have always liked it and owned it many times. Never works out. Extreme Networks GAAP EPS of $0.15 beats by $0.12, revenue of $278.2M beats by $9.24M, updates Q1 guidance Jul. 27, 2022 7:09 AM ETExtreme Networks, Inc. (EXTR) Extreme Networkspress release(NASDAQ:EXTR): Q4 GAAP EPS of $0.15beats by $0.12. Revenue of $278.2M (flat Y/Y)beats by $9.24M. Q1 Guidance: Revenue of $279M-$289M vs consensus of 278.51M; Adj EPS of $0.15-$0.20 vs consensus of $0.18
Teledyne Non-GAAP EPS of $4.43 beats by $0.05, revenue of $1.36B in-line, raises FY earning guidance Jul. 27, 2022 7:00 AM ETTeledyne Technologies Incorporated (TDY) Teledynepress release(NYSE:TDY): Q2 Non-GAAP EPS of $4.43beats by $0.05. Revenue of $1.36B (+21.4% Y/Y) in-line. Revising full year 2022 GAAP earnings outlook to $15.13 to $15.45 diluted earnings per share, compared with the prior outlook of $15.34 to $15.66, and full year non-GAAP earnings outlook to $17.45 to $17.70 vs consensus of $15.59, compared with the prior outlook of $17.75 to $18.00
American Electric Power Non-GAAP EPS of $1.20 beats by $0.01, revenue of $4.6B beats by $620M Jul. 27, 2022 6:59 AM ETAmerican Electric Power Company, Inc. (AEP) American Electric Powerpress release(NASDAQ:AEP): Q2 Non-GAAP EPS of $1.20beats by $0.01. Revenue of $4.6B (+21.1% Y/Y)beats by $620M. Company reaffirms 2022 operating earnings guidance range of $4.87 to $5.07 and 6% to 7% long-term growth rate. Continued focus on a responsible clean energy transition through regulated renewables and grid investments.
Speaking of slow movers and stocks I sold out of-- Equinor Non-GAAP EPS of $2.11, revenue of $36.46B beats by $1.32B, increases buyback Jul. 27, 2022 1:46 AM ETEquinor ASA (EQNR) Equinorpress release(NYSE:EQNR): Q2 Non-GAAP EPS of $2.11. Revenue of $36.46B (+108.8% Y/Y)beats by $1.32B. Organic capital expenditures are estimated at an annual average of around USD 10 billion for 2022-2023 and at an annual average of around USD 12 billion for 2024-20251 . Production for 2022 is estimated to be around 2% above 2021 level.
STFU DEPT- Roku price target lowered to $150 from $240 at Benchmark 07:57 ROKU <---BOOOOOOOO! All this stk does is get downgraded.
STFU DEPT #2- I can't catch a break here. Boyd Gaming price target lowered to $66 from $73 at Deutsche Bank 07:32 BYD Deutsche Bank analyst Carlo Santarelli lowered the firm's price target on Boyd Gaming to $66 from $73 and keeps a Buy rating on the shares. The company delivered upside to forecasts, with the beat stemming primarily from the Las Vegas locals and downtown segments, Santarelli tells investors in a research note.
There is very little news today so I republish the RON Report. The son of my money manager thinks this may have changed people's perception of the market and I may have contributed directly to today's rally.